Aktis Oncology (NASDAQ:AKTS) Shares Gap Down – Here’s Why

Aktis Oncology (NASDAQ:AKTS)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $19.55, but opened at $18.50. Aktis Oncology shares last traded at $18.7050, with a volume of 9,999 shares changing hands.

Analyst Ratings Changes

A number of brokerages have issued reports on AKTS. HC Wainwright boosted their price objective on shares of Aktis Oncology from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. TD Cowen started coverage on Aktis Oncology in a report on Tuesday, February 3rd. They set a “buy” rating on the stock. William Blair started coverage on Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating on the stock. Leerink Partners started coverage on Aktis Oncology in a report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 target price on the stock. Finally, Weiss Ratings started coverage on shares of Aktis Oncology in a research report on Tuesday, May 12th. They issued a “sell (d)” rating on the stock. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $32.00.

Aktis Oncology Stock Performance

The business’s fifty day moving average is $18.65.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The firm had revenue of $1.87 million during the quarter. Analysts predict that Aktis Oncology will post -1.56 earnings per share for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.